Cutaneous Small-Vessel Vasculitis following Dabigatran, Rivaroxaban, and Apixaban Use in Patients with Atrial Fibrillation: A Propensity Score Matched Analysis

Basic Details
Date Posted
Wednesday, February 3, 2021
Status
Complete
Medical Product
apixaban
dabigatran
direct oral anticoagulant (DOAC)
rivaroxaban
warfarin
Health Outcome(s)
cutaneous small-vessel vasculitis
Description

This analysis investigates the risk of cutaneous small-vessel vasculitis (CSVV) associated with the use of dabigatran, rivaroxaban, apixaban, and warfarin among patients with atrial fibrillation in the Sentinel Distributed Database (SDD).

The study period includes data from October 19, 2010 to February 29, 2020. We distributed this request to 16 Data Partners on September 15, 2020.

The analytic package associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.